Clinical Trial Hub
The iCMLf Clinical Trials Hub brings together up-to-date listings of clinical trials investigating new compounds for CML, making it easier for clinicians, researchers, and advocates to stay informed. This curated, CML-specific resource draws data from ClinicalTrials.gov into a streamlined webpage, with a searchable, downloadable spreadsheet to help tailor and refine your search.
What you’ll find
A focused view of trials investigating novel agents and emerging therapeutic approaches in CML. Current compounds include (in alphabetical order); asciminib, ELVN-001, HS-10382, olverembatinib, radotinib, TERN-701, TGRX-679, TQB3911.
Two categorised lists of CML trials
Recruiting now – Trials currently enrolling patients (and potentially sites)
Not yet recruiting – Studies in preparation stages
Key information at a glance
- Study descriptions
- Sponsor details
- Estimated patient enrolment
- Site locations and recruitment status
A downloadable, searchable Excel file to filter by sponsor, compound, or trial phase
(Updated regularly; the current file is from February 2026)
Why this matters
This centralised resource empowers patients, physicians, and advocates by improving access to emerging treatment options and supporting informed decisions in CML care. It helps connect people with clinical trials more quickly and efficiently - wherever they are in the world.
View the resource
Recruiting now – Trials currently enrolling patients (and potentially sites)
Not yet recruiting – Studies in preparation stages
Download our searchable Excel file to filter by sponsor, compound, or trial phase:
We’ll continue to update this resource regularly so you can stay informed on the latest developments in CML research.
Disclaimer
The information presented in this overview has been sourced from www.clinicaltrials.gov and reflects data available as of the date listed above. While the iCMLf strives to ensure accuracy, it is not responsible for any errors, updates, or changes that may have occurred since that date. This list is provided solely for informational purposes and is organized alphabetically by investigational compound. The iCMLf does not endorse or recommend any specific clinical trial, investigational drug, or sponsor mentioned. For the most current and comprehensive details - including eligibility criteria, study locations, and contact information - please consult the official listing on clinicaltrials.gov.